Draulio Araújo on the path from ayahuasca research to controlled DMT trials for treatment-resistant depression
Summary
Draulio B. Araújo describes how his group moved from studying consciousness during ayahuasca experiences to clinical research on depression and inhaled DMT. A 2019 randomized trial suggested a rapid antidepressant effect from ayahuasca in treatment-resistant depression, while a 2025 open-label Phase 2a DMT study found rapid symptom improvements in 14 patients but could not separate drug effects from expectancy, clinical support, or natural symptom variation. His ongoing Phase 2b trial in Brazil randomizes 140 participants to higher-dose DMT or a low-dose active comparator, addressing the difficult problem of psychedelic blinding. Araújo emphasizes that efficacy requires superiority over the control condition, independent assessment, broader outcomes such as suicidality, functioning and quality of life, and sustained benefit. He also cautions that neuroimaging findings are not yet mechanisms of antidepressant action. A negative, well-designed trial would still clarify whether the early signal survives rigorous testing.